Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Primary completion Nov 20, 2026Sponsor estimateNo phase registeredNCT06653387A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in...InspireMD · Carotid Artery DiseasesRecruitingNSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2026Sponsor estimateNo phase registeredNCT07356323A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic SurgerySolventum US LLC · Arthroplasty Replacement, KneeRecruitingSOLVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2026Sponsor estimatePhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 1NCT06545331Study of XB010 in Subjects With Solid TumorsExelixis · Locally Advanced or Metastatic Solid TumorsRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 2NCT06567782A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III...GlaxoSmithKline · Neoplasms, ColonRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 3NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2026Sponsor estimatePhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2026Sponsor estimateNo phase registeredNCT06376097Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.AstraZeneca · Lung CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2026Sponsor estimatePhase 3NCT06641466A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePfizer · Menstrual MigraineRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06063850AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyUniQure Biopharma B.V. · Mesial Temporal Lobe EpilepsyRecruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06643884Suprachoroidal Administration in Subjects With Metastases to the ChoroidAura Biosciences · Eye CancerRecruitingAURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced CancersImmunocore Ltd · CancerRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg...BeOne Medicines · Chronic Spontaneous UrticariaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07361276Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemAstraZeneca · HypertensionRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 DiabetesRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07539194Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic...Innate srl · Meniscus TearsRecruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07889219Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A VaccineSinovac Biotech Co., Ltd · Hepatitis ARecruitingSVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07946575A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in...Trevi Therapeutics · Healthy ParticipantsRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 40 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.